Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.
Robertson CC., Inshaw JRJ., Onengut-Gumuscu S., Chen W-M., Santa Cruz DF., Yang H., Cutler AJ., Crouch DJM., Farber E., Bridges SL., Edberg JC., Kimberly RP., Buckner JH., Deloukas P., Divers J., Dabelea D., Lawrence JM., Marcovina S., Shah AS., Greenbaum CJ., Atkinson MA., Gregersen PK., Oksenberg JR., Pociot F., Rewers MJ., Steck AK., Dunger DB., Type 1 Diabetes Genetics Consortium None., Wicker LS., Concannon P., Todd JA., Rich SS.
We report the largest and most diverse genetic study of type 1 diabetes (T1D) to date (61,427 participants), yielding 78 genome-wide-significant (P